Genmab Announces Financial Results for the First Half of 2020
(WorldNews Environment)

Supporting Materials: 120820_CA34_Genmab Q2 2020 Interim Report PDF Version August 12, 2020; Copenhagen, Denmark; Interim Report for the First Half of 2020 Highlights ·Genmab and AbbVie enter into broad oncology collaboration; USD 750 million upfront payment with total potential milestone and opt-in payments of up to USD 3.15 billion ·Very favorable topline results announced from Phase 2 clinical trial of tisotumab vedotin in recurrent or metastatic cervical cancer ·Subcutaneous formulation of DARZALEX® (daratumumab), known as DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) in the U.S., approved in U.S. and Europe for certain multiple myeloma indications ·Positive topline results in...